PLANTATION, Fla., Aug. 26 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to appear as a
featured guest on BioTech Today, an Internet-based talk radio show focusing on
biotechnology, nanotechnology and life sciences. The program will air live on
Wednesday, September 1st from 4:00 p.m. to 5:00 p.m. (Eastern time).
Listeners can access the show -- live and archived -- at
http://www.biotechtoday.net and at http://www.viragen.com.
Viragen has been invited on the program to discuss its multi-faceted
approach to developing novel technologies for the treatment of cancer and the
status of its portfolio of oncology products.
Guests from Viragen scheduled to appear on BioTech Today include:
* Charles A. Rice, President and CEO
* Professor William H. Stimson, Ph.D., Director of Research (Emeritus)
Viragen also announced that the Company is scheduled to present its
oncology technologies at the United Kingdom/Lyon Rhone-Alps Immunotherapy of
Cancer Meetings in France on September 20th and 21st.
"This upcoming event in Lyon is one of a number of professional meetings
that we are planning to attend and present at throughout the remainder of this
year," stated Dr. Karen Jervis, Viragen's Director of Technology and Projects
Coordinator. "Based on our progress to date and pending milestones that we
are expecting to report, it is important that we continue to raise our
visibility by reaching a variety of investor, scientific and corporate
audiences."
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746;
Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "will," "should," "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results to be materially different
from any future results, performance or achievements expressed or implied by
such statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made. Guests scheduled to appear on the program "BioTech
Today" are potentially subject to be replaced, rescheduled or canceled due to
unforeseen conflicts.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
e-mail, dcalder@viragen.com
|
